{"id":77070,"date":"2026-08-28T20:59:38","date_gmt":"2026-08-28T12:59:38","guid":{"rendered":"https:\/\/flcube.com\/?p=77070"},"modified":"2026-08-28T20:59:39","modified_gmt":"2026-08-28T12:59:39","slug":"ausperbio-raises-usd-120m-series-c-to-advance-ahb-137-phase-iii-trial-and-oligonucleotide-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77070","title":{"rendered":"AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>AusperBio<\/strong> announced the completion of a <strong>USD 120m Series C financing round<\/strong>, a substantial capital raise that will primarily support the Phase III registrational clinical trial and commercialization preparation for its lead candidate <strong>AHB-137<\/strong>. Backed by a globally renowned strategic investment institution and a roster of top-tier healthcare funds, the round underscores strong investor conviction in <strong>AusperBio&#8217;s<\/strong> innovative oligonucleotide platform at a time when the modality is attracting intense global interest.<\/p>\n\n\n\n<h2 id=\"h-financing-overview\" class=\"wp-block-heading\">Financing Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Company<\/td><td><strong>AusperBio<\/strong><\/td><\/tr><tr><td>Round Type<\/td><td>Series C<\/td><\/tr><tr><td>Size<\/td><td>USD 120m<\/td><\/tr><tr><td>Lead Investor<\/td><td>A globally renowned strategic investment institution<\/td><\/tr><tr><td>New Investor<\/td><td>RA Capital<\/td><\/tr><tr><td>Existing Investors<\/td><td>Hankang Capital, Sherpa Healthcare Partners, InnoPinnacle Fund, Qiming Venture Partners, Yuanbio Venture Capital, DCM VGC<\/td><\/tr><tr><td>Date<\/td><td>28 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-use-of-proceeds\" class=\"wp-block-heading\">Use of Proceeds<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AHB-137 Phase III:<\/strong> Primarily fund the registrational clinical trial for <strong>AHB-137<\/strong>, the company&#8217;s lead oligonucleotide candidate<\/li>\n\n\n\n<li><strong>Commercialization Readiness:<\/strong> Prepare commercial infrastructure ahead of potential <strong>AHB-137<\/strong> launch<\/li>\n\n\n\n<li><strong>AHB-171 Acceleration:<\/strong> Speed development of <strong>AHB-171<\/strong>, the next key program in the pipeline<\/li>\n\n\n\n<li><strong>Combination Therapies:<\/strong> Advance next-generation combination therapy development<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Further broaden <strong>AusperBio&#8217;s<\/strong> innovative oligonucleotide product pipeline<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-investor-roster-amp-signaling\" class=\"wp-block-heading\">Investor Roster &amp; Signaling<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Category<\/th><th>Investors<\/th><th>Signal<\/th><\/tr><\/thead><tbody><tr><td>Lead<\/td><td>Globally renowned strategic institution<\/td><td>Strategic validation of platform and lead asset<\/td><\/tr><tr><td>New<\/td><td>RA Capital<\/td><td>Entry of a major global healthcare specialist fund<\/td><\/tr><tr><td>Existing<\/td><td>Hankang Capital, Sherpa Healthcare Partners, InnoPinnacle Fund, Qiming Venture Partners, Yuanbio Venture Capital, DCM VGC<\/td><td>Continued commitment across funding rounds<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The round was led by a globally renowned strategic investment institution, with participation from new investor <strong>RA Capital<\/strong> and continued support from existing investors including <strong>Hankang Capital, Sherpa Healthcare Partners, InnoPinnacle Fund, Qiming Venture Partners, Yuanbio Venture Capital, and DCM VGC<\/strong>. The participation of RA Capital \u2014 one of the world&#8217;s most prominent healthcare-focused investment firms \u2014 adds international credibility to <strong>AusperBio&#8217;s<\/strong> oligonucleotide platform as it approaches the registrational stage.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Late-Stage Capital:<\/strong> A USD 120m Series C concentrated on a Phase III registrational trial signals <strong>AusperBio<\/strong> is nearing the commercial inflection point for <strong>AHB-137<\/strong><\/li>\n\n\n\n<li><strong>Oligonucleotide Momentum:<\/strong> The raise rides the global surge in oligonucleotide therapeutics, a modality increasingly favored for its precision and expanding target space<\/li>\n\n\n\n<li><strong>Commercial Runway:<\/strong> Dedicated commercialization preparation funding indicates the company intends to build its own launch capability rather than rely solely on partnership<\/li>\n\n\n\n<li><strong>Pipeline Depth:<\/strong> Continued investment in <strong>AHB-171<\/strong> and combination therapies diversifies the company&#8217;s value drivers beyond a single lead asset<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2013 This brief contains forward-looking statements regarding clinical development, commercialization plans, and pipeline expansion. Financing completion does not guarantee regulatory or commercial outcomes. Not investment advice.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AusperBio announced the completion of a USD 120m Series C financing round, a substantial capital&#8230;<\/p>\n","protected":false},"author":1,"featured_media":77073,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10,4908],"tags":[119,20,89],"class_list":["post-77070","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-pic","tag-ausperbio","tag-finance","tag-viral-hepatitis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AusperBio announced the completion of a USD 120m Series C financing round, a substantial capital raise that will primarily support the Phase III registrational clinical trial and commercialization preparation for its lead candidate AHB-137. Backed by a globally renowned strategic investment institution and a roster of top-tier healthcare funds, the round underscores strong investor conviction in AusperBio&#039;s innovative oligonucleotide platform at a time when the modality is attracting intense global interest.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77070\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline\" \/>\n<meta property=\"og:description\" content=\"AusperBio announced the completion of a USD 120m Series C financing round, a substantial capital raise that will primarily support the Phase III registrational clinical trial and commercialization preparation for its lead candidate AHB-137. Backed by a globally renowned strategic investment institution and a roster of top-tier healthcare funds, the round underscores strong investor conviction in AusperBio&#039;s innovative oligonucleotide platform at a time when the modality is attracting intense global interest.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77070\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T12:59:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T12:59:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2806.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77070#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77070\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline\",\"datePublished\":\"2026-08-28T12:59:38+00:00\",\"dateModified\":\"2026-08-28T12:59:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77070\"},\"wordCount\":436,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77070#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2806.webp\",\"keywords\":[\"AusperBio\",\"Finance\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Deals\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77070#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77070\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77070\",\"name\":\"AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77070#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77070#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2806.webp\",\"datePublished\":\"2026-08-28T12:59:38+00:00\",\"dateModified\":\"2026-08-28T12:59:39+00:00\",\"description\":\"AusperBio announced the completion of a USD 120m Series C financing round, a substantial capital raise that will primarily support the Phase III registrational clinical trial and commercialization preparation for its lead candidate AHB-137. Backed by a globally renowned strategic investment institution and a roster of top-tier healthcare funds, the round underscores strong investor conviction in AusperBio's innovative oligonucleotide platform at a time when the modality is attracting intense global interest.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77070#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77070\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77070#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2806.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2806.webp\",\"width\":1080,\"height\":608,\"caption\":\"AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77070#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"AusperBio announced the completion of a USD 120m Series C financing round, a substantial capital raise that will primarily support the Phase III registrational clinical trial and commercialization preparation for its lead candidate AHB-137. Backed by a globally renowned strategic investment institution and a roster of top-tier healthcare funds, the round underscores strong investor conviction in AusperBio's innovative oligonucleotide platform at a time when the modality is attracting intense global interest.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77070","og_locale":"en_US","og_type":"article","og_title":"AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline","og_description":"AusperBio announced the completion of a USD 120m Series C financing round, a substantial capital raise that will primarily support the Phase III registrational clinical trial and commercialization preparation for its lead candidate AHB-137. Backed by a globally renowned strategic investment institution and a roster of top-tier healthcare funds, the round underscores strong investor conviction in AusperBio's innovative oligonucleotide platform at a time when the modality is attracting intense global interest.","og_url":"https:\/\/flcube.com\/?p=77070","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-28T12:59:38+00:00","article_modified_time":"2026-08-28T12:59:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2806.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77070#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77070"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline","datePublished":"2026-08-28T12:59:38+00:00","dateModified":"2026-08-28T12:59:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77070"},"wordCount":436,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=77070#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2806.webp","keywords":["AusperBio","Finance","Viral hepatitis"],"articleSection":["Company","Deals","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77070#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77070","url":"https:\/\/flcube.com\/?p=77070","name":"AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=77070#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=77070#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2806.webp","datePublished":"2026-08-28T12:59:38+00:00","dateModified":"2026-08-28T12:59:39+00:00","description":"AusperBio announced the completion of a USD 120m Series C financing round, a substantial capital raise that will primarily support the Phase III registrational clinical trial and commercialization preparation for its lead candidate AHB-137. Backed by a globally renowned strategic investment institution and a roster of top-tier healthcare funds, the round underscores strong investor conviction in AusperBio's innovative oligonucleotide platform at a time when the modality is attracting intense global interest.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77070#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77070"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=77070#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2806.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2806.webp","width":1080,"height":608,"caption":"AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77070#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2806.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77070"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77070\/revisions"}],"predecessor-version":[{"id":77074,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77070\/revisions\/77074"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/77073"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}